换一批Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
第一作者：
Karoline V,Gleixner
第一单位：
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Institute of Immunology, Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, A-1090 Vienna, Austria.
作者：
医学主题词
青少年(Adolescent);成年人(Adult);老年人(Aged);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);苯甲酰胺类(Benzamides);细胞周期蛋白质类(Cell Cycle Proteins);药物释放系统(Drug Delivery Systems);药物评价, 临床前(Drug Evaluation, Preclinical);抗药性, 肿瘤(Drug Resistance, Neoplasm);女(雌)性(Female);融合蛋白质类, bcr-abl(Fusion Proteins, bcr-abl);基因表达调控, 酶学(Gene Expression Regulation, Enzymologic);基因表达调控, 白血病(Gene Expression Regulation, Leukemic);人类(Humans);K562细胞(K562 Cells);白血病, 髓系, 慢性, BCR-ABL阳性(Leukemia, Myelogenous, Chronic, BCR-ABL Positive);男(雄)性(Male);中年人(Middle Aged);哌嗪类(Piperazines);蛋白激酶抑制剂(Protein Kinase Inhibitors);原癌基因蛋白质类(Proto-Oncogene Proteins);蝶啶类(Pteridines);嘧啶类(Pyrimidines)
DOI
10.1158/0008-5472.CAN-09-2181
PMID
20145140
发布时间
2023-12-13
- 浏览16
Cancer research
1513-23页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
